Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, bertilimumab, is entering phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid with additional studies planned for Crohn’s disease and severe asthma. For more information, visit the company’s website at www.immunepharmaceuticals.com.